Bruker Corporation (NASDAQ:BRKR) CEO Frank H. Laukien acquired 2,335 shares of the stock in a transaction dated Thursday, August 10th. The stock was acquired at an average cost of $27.39 per share, with a total value of $63,955.65. Following the completion of the transaction, the chief executive officer now owns 37,791,386 shares in the company, valued at approximately $1,035,106,062.54. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Bruker Corporation (BRKR) traded down 1.35% during trading on Thursday, reaching $27.07. The company’s stock had a trading volume of 418,973 shares. Bruker Corporation has a one year low of $19.59 and a one year high of $30.22. The firm has a market cap of $4.32 billion, a PE ratio of 26.99 and a beta of 1.10. The company has a 50-day moving average of $28.68 and a 200 day moving average of $25.61.

Bruker Corporation (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.03. The company had revenue of $414.90 million during the quarter, compared to the consensus estimate of $384.75 million. Bruker Corporation had a net margin of 9.65% and a return on equity of 27.18%. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.20 earnings per share. Analysts expect that Bruker Corporation will post $1.12 EPS for the current fiscal year.

Bruker Corporation announced that its Board of Directors has authorized a stock buyback plan on Friday, May 12th that permits the company to buyback $225.00 million in shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s leadership believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at

Several large investors have recently made changes to their positions in BRKR. SG Americas Securities LLC purchased a new stake in shares of Bruker Corporation during the second quarter valued at $111,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Bruker Corporation by 11.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock valued at $133,000 after buying an additional 467 shares during the period. Smithfield Trust Co. purchased a new stake in shares of Bruker Corporation during the second quarter valued at $138,000. Advisory Services Network LLC purchased a new stake in shares of Bruker Corporation during the first quarter valued at $150,000. Finally, Capstone Asset Management Co. bought a new stake in shares of Bruker Corporation during the first quarter valued at about $203,000. 67.00% of the stock is owned by institutional investors.

Several research analysts have recently weighed in on the company. BidaskClub lowered Bruker Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday. Barclays PLC reissued an “equal weight” rating and issued a $30.00 price objective (up from $26.00) on shares of Bruker Corporation in a research report on Monday, July 17th. Cowen and Company reaffirmed a “hold” rating and issued a $29.00 target price on shares of Bruker Corporation in a research report on Friday, July 14th. Wells Fargo & Company lowered Bruker Corporation from a “market perform” rating to an “underperform” rating in a research report on Wednesday, July 12th. Finally, Zacks Investment Research raised Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research report on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the stock. Bruker Corporation has a consensus rating of “Hold” and a consensus price target of $27.00.

About Bruker Corporation

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Insider Buying and Selling by Quarter for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.